| Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer’s disease: randomized, double-blind, placebo-controlled study M Timmers, JR Streffer, A Russu, Y Tominaga, H Shimizu, A Shiraishi, ... Alzheimer's research & therapy 10, 1-18, 2018 | 104 | 2018 |
| Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans G Salvadore, P Bonaventure, A Shekhar, PL Johnson, B Lord, ... Translational Psychiatry 10 (1), 308, 2020 | 45 | 2020 |
| A multiple-dose double-blind randomized study to evaluate the safety, pharmacokinetics, pharmacodynamics and analgesic efficacy of the TRPV1 antagonist JNJ-39439335 (mavatrep) P Manitpisitkul, CM Flores, JA Moyer, G Romano, K Shalayda, K Tatikola, ... Scandinavian journal of pain 18 (2), 151-164, 2018 | 42 | 2018 |
| Motor cortical excitability and paired-associative stimulation-induced plasticity in amnestic mild cognitive impairment and Alzheimer’s disease A Meder, I Liepelt-Scarfone, P Sulzer, D Berg, C Laske, O Preische, ... Clinical neurophysiology 132 (9), 2264-2273, 2021 | 13 | 2021 |
| The impact of experimental and calculated error on the performance of affinity predictions G Tresadern, K Tatikola, J Cabrera, L Wang, R Abel, H Van Vlijmen, ... Journal of Chemical Information and Modeling 62 (3), 703-717, 2022 | 10 | 2022 |
| O1‐10‐05: Pharmacodynamics of the Oral Bace Inhibitor JNJ‐54861911 in Early Alzheimer's Disease J Streffer, A Börjesson-Hanson, B Van Broeck, P Smekens, M Timmers, ... Alzheimer's & Dementia 12, P199-P200, 2016 | 9 | 2016 |
| F13. Safety, tolerability, pharmacokinetic and pharmacodynamic properties of the selective orexin-1 receptor antagonist JNJ-61393215: Results from the first-in-human and … G Salvadore, S Brooks, B Cathy, J Moyer, B Shireman, P Bonaventure, ... Biological Psychiatry 85 (10), S217-S218, 2019 | 6 | 2019 |
| Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer’s disease: randomized, double-blind, placebo-controlled study … M Timmers, JR Streffer, A Russu, Y Tominaga, H Shimizu, A Shiraishi, ... | 5 | 2018 |
| Survey and Recommendations on the Use of P-Values Driving Decisions in Nonclinical Pharmaceutical Applications S Altan, D Amaratunga, J Cabrera, J Garren, H Geys, J Kolassa, ... Statistics in Biopharmaceutical Research 15 (2), 343-358, 2023 | 4 | 2023 |
| Niraparib shows superior tissue distribution and efficacy in a prostate cancer bone metastasis model compared with other PARP inhibitors LA Snyder, R Damle, S Patel, J Bohrer, A Fiorella, J Driscoll, R Hawkins, ... Molecular Cancer Therapeutics 21 (7), 1115-1124, 2022 | 4 | 2022 |
| Transvaginal ultrasound is superior to transabdominal ultrasound in the identification of a short cervix JS Jayakumaran, S Egan, M Tatikola, M Schuster, CM Duzyj, JS Brandt, ... American Journal of Obstetrics & Gynecology 221 (4), 365-367, 2019 | 4 | 2019 |
| Implementing Efficient Peptoid‐Mediated Delivery of RNA‐Based Therapeutics to the Vocal Folds S Mukudai, I Kraja, R Bing, DM Nalband, M Tatikola, N Hiwatashi, ... Laryngoscope investigative otolaryngology 4 (6), 640-644, 2019 | 3 | 2019 |
| Analysis of continuous monitoring device data J Wang, J Cabrera, D Sargsyan, K Tatikola, KL Tsui Journal of Biopharmaceutical Statistics, 1-9, 2025 | | 2025 |
| The partnership between statisticians and the Institutional Animal Care and Use Committee (IACUC) D Potter, T Bradstreet, D Sargsyan, X Tan, V Bonato, D Li, J Liang, ... Pharmaceutical Statistics 24 (1), e2390, 2025 | | 2025 |
| Estimating the Strength of Binding Affinity via Delta–Delta‐G for Hit Screening After a Deming Regression Calibration K Tatikola, J Cabrera Pharmaceutical Statistics 24 (1), e2460, 2025 | | 2025 |
| Addressing Class Imbalance in Bayesian Classification Through Posterior Probability Adjustment V Nassiri, F Tekle, K Tatikola, H Geys Biometrical Journal 66 (8), e70004, 2024 | | 2024 |
| Improved automated spot counting and modeling with bias correction CP Lin, Y Duan, D Sargsyan, H Geys, J Sendecki, K Tatikola, S Mohanty, ... Journal of Biopharmaceutical Statistics, 1-7, 2024 | | 2024 |
| Niraparib shows superior tissue distribution and efficacy in a prostate bone metastasis model compared with other PARP inhibitors LA Snyder, RN Damle, S Patel, J Bohrer, J Driscoll, R Hawkins, ... Cancer Research 80 (16_Supplement), 4128-4128, 2020 | | 2020 |
